<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ROSIGLITAZONE MALEATE <img border="0" src="../images/pr.gif"/></span><br/>(ros-i-glit'a-zone)<br/><span class="topboxtradename">Avandia<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">antidiabetic</span>; <span class="classification">thiazolidinediones</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 4 mg, 8 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antidiabetic agent that lowers blood sugar levels by improving target cell response to insulin in Type 2 diabetics. It reduces
         cellular insulin resistance and decreases hepatic glucose output (gluconeogenesis).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces hyperglycemia and hyperlipidemia, thus improving hyperinsulinemia without stimulating pancreatic insulin secretion.
         Indicated by decreased HbA<sub>1c</sub>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet in the treatment of Type 2 diabetes. May also be used in combination with metformin.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rosiglitazone; pregnancy (category C), lactation; active hepatic disease or ALT &gt;2.5 times normal.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>As monotherapy in Type 1 diabetes mellitus or diabetic ketoacidosis; cardiovascular disease, particularly hypertensive patients
         with New York Heart Association Class III and IV cardiac status (e.g., CHF); hepatic impairment. Safety &amp; efficacy in children
         
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start at 4 mg q.d. or 2 mg b.i.d., may increase after 12 wk (max: 8 mg/d in 12 divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not initiate therapy if baseline serum ALT &gt;2.5.</li>
<li>Store at 15°30° C (59°86° F) in tight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Edema, anemia, headache, back pain, fatigue. <span class="typehead">CV:</span> edema, fluid retention, exacerbation of heart failure. <span class="typehead">GI:</span> Diarrhea. <span class="typehead">Respiratory:</span> Upper respiratory tract infection, sinusitis. <span class="typehead">Other:</span> Hyperglycemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Insulin</b> may increase risk of heart failure or edema; enhance hypoglycemia with <span class="classification">oral antidiabetic agents</span>, <b>ketoconazole.</b>
<span class="typehead">Herbal:</span>
<b>Garlic,</b>
<b>ginseng</b> may potentiate hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 99% absorbed from GI tract. <span class="typehead">Peak:</span> 1 h, food delays time to peak by 1.75 h. <span class="typehead">Duration:</span> &gt;24 h. <span class="typehead">Distribution:</span> &gt;99% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in liver by CYP2C8 to inactive metabolites. <span class="typehead">Elimination:</span> 64% excreted in urine, 23% excreted in feces. <span class="typehead">Half-Life:</span> 34 h. Moderate to severe liver disease increases serum concentrations and increases half-life by 2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypoglycemia (possible when insulin/sulfonylureas are coadministered).</li>
<li>Monitor for S&amp;S of CHF or exacerbation of symptoms with preexisting CHF.</li>
<li>Lab tests: Liver function and serum ALT at baseline, then q2mo for first year; then periodically (more often when elevated);
            periodic HbA<sub>1C</sub>, Hgb &amp; Hct, and lipid profile.
         </li>
<li>Withhold drug and notify physician if ALT &gt;3 times normal or patient jaundiced.</li>
<li>Monitor weight and notify physician of development of edema.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Have blood tested for liver function every 2 mo for first year; then periodically.</li>
<li>Be aware that resumed ovulation is possible in nonovulating premenopausal women.</li>
<li>Use or add barrier contraceptive if using hormonal contraception.</li>
<li>Report immediately to physician: S&amp;S of liver dysfunction such as unexplained anorexia, nausea, vomiting, abdominal pain,
            fatigue, dark urine; or S&amp;S of fluid retention such as weight gain, edema, or activity intolerance.
         </li>
<li>Combination therapy: May need adjustment of other antidiabetic drugs to avoid hypoglycemia.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>